Broker Ratings

DaVita Inc. – Consensus ‘hold’ rating and -.7% Downside Potential

DaVita Inc. which can be found using ticker (DVA) now have 6 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between $115.00 and $90.00 calculating the average target price we see $105.67. Now with the previous closing price of $106.43 this is indicating there is a potential downside of -.7%. It’s also worth noting that there is a 50 day moving average of $90.78 and the 200 day MA is $93.68. The market capitalization for the company is 9.67B. The stock price for the company is currently $105.82 USD

The potential market cap would be $9,596,965,294 based on the market consensus.

The company has a dividend yield of 3.8%. Other points of data to note are a P/E ratio of 16.43, revenue per share of $131.29 and a 5.43% return on assets.

DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company’s operations are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services, clinical research programs, and transplant software business, as well as international operations. The Company operates approximately 2,724 outpatient dialysis centers in the United States.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    DaVita Inc. (DVA) Investor Outlook: Evaluating Growth Potential Amid a 16.50% Upside

    DaVita Inc. (NYSE: DVA), a key player in the healthcare sector, remains a focal point for investors interested in the medical care facilities industry. With a market capitalization of $9.24

    DaVita Inc. (DVA) Stock Analysis: Evaluating the 19.56% Potential Upside

    For investors eyeing the healthcare sector, DaVita Inc. (NYSE: DVA) presents an intriguing opportunity, particularly given its potential upside of 19.56% based on current analyst evaluations. As a leading provider

    DaVita Inc. (DVA) Stock Analysis: Evaluating a 22% Potential Upside for Healthcare Investors

    DaVita Inc. (NYSE: DVA), a key player in the healthcare sector specializing in kidney dialysis services, presents a compelling case for investors seeking exposure to the medical care facilities industry.

    DaVita Inc. (DVA) Stock Analysis: Strong Revenue Growth and a 17% Upside Potential

    DaVita Inc. (NYSE: DVA), a prominent player in the healthcare sector, specifically within medical care facilities, is making waves with its financial performance and promising analyst projections. With a market

    DaVita Inc. (DVA) Stock Analysis: Evaluating a 17.35% Upside in the Healthcare Sector

    Investors looking to capture value in the healthcare sector might want to consider DaVita Inc. (NYSE: DVA), a key player in the medical care facilities industry, with a market capitalization

    DaVita Inc. (DVA) Stock Analysis: Insights into Potential 17.35% Upside for Healthcare Investors

    DaVita Inc. (NYSE: DVA), a leading provider of kidney dialysis services in the United States, is catching the attention of investors due to its notable potential upside of 17.35%. With

      Search

      Search